Abbott (NYSE:ABT) posted its third quarter financial results yesterday, meeting its own forecast and the consensus set by analysts on Wall Street. The healthcare giant also narrowed its earnings outlook for the rest of the year.
Abbott noted particularly high gains in revenue for its medical device division – sales were up 8.4% to $2.82 billion, in part driven by double-digit growth for its diabetes business.
Get the full story at our sister site, Drug Delivery Business News.
The post Abbott CEO on Libre: ‘We’re just getting started’ appeared first on MassDevice.
from MassDevice https://ift.tt/2CqjFnC
Cap comentari:
Publica un comentari a l'entrada